NEW YORK (GenomeWeb News) - Shares in Affymetrix were up 6.25, or $1.20, at $20.41 in mid-afternoon share after the company late yesterday said it would have to restate its financial results as far back as 1997 after an internal review into its stock-option granting practices turned up “certain documentation lapses.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.